Oct.08 -- Kerry Blanchard, chief executive officer of Chinese biotech firm Everest Medicines Ltd., talks about the company's initial public offering in Hong Kong and its growth strategy. Everest focuses on developing drugs already discovered or marketed overseas for the China and Asia markets by licensing development and commercialization rights from the innovators. The stock rose more than 30 percent in its trading debut. Blanchard speaks on "Bloomberg Markets: Asia."
View on YouTube
No comments:
Post a Comment